Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities

Genes Chromosomes and Cancer

Volumn 47, Issue 8, 2008, Pages 712-727

  Haruta, Masayuki ^a   Arai, Yasuhito ^b   Sugawara, Waka ^a   Watanabe, Naoki ^a   Honda, Shohei ^a   Ohshima, Junjiro ^a   Soejima, Hidenobu ^c   Nakadate, Hisaya ^d   Okita, Hajime ^d   Hata, Jun Ichi ^d   Fukuzawa, Masahiro ^d   Kaneko, Yasuhiko ^a,d  

^a SAITAMA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d Japan Wilms Tumor Study Group JWiTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MESSENGER RNA; SOMATOMEDIN B; WT1 PROTEIN;

ARTICLE; CHROMOSOME 11P; CLINICAL ARTICLE; DNA METHYLATION; DNA MICROARRAY; FATHER; FEMALE; GENE DELETION; GENE DUPLICATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENOME IMPRINTING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; KIDNEY; MALE; MOTHER; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; UNIPARENTAL DISOMY;

BETA CATENIN; DNA METHYLATION; FEMALE; GENOMIC IMPRINTING; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MUTATION; WILMS TUMOR; WT1 PROTEINS;

EID: 45349090812     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20572     Document Type: Article

References (42)

1. Beckwith JB, Palmer NF. 1978. Histopathology and prognosis of Wilms tumors: Results from the first national Wilms' tumor study. Cancer 41:1937-1948.
2. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Bliek J, Schofield PN, Reik W, Macdonald F, Maher ER. 2005. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 13:1025-1032.
3. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K. 2004. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. Hum Mol Genet 13:405-415.
4. d'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, Fernbach D, Hrabovsky E, Jones B, Kelalis P, Othersen HB, Tefft M, Thomas PRM. 1989. Treatment of Wilms' tumor. Results of the third national Wilms' tumor study. Cancer 64:349-360.
5. Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A, Spraggon L, Nick Hastie N. 2004. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 13:235-246.
6. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ, III. 1992. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257:674-678.
7. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB. 2005. Insulin-like growth factor ligands, receptors Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145-153.
8. Fukuzawa R, Heathcott RW, More HE, Reeve AE. 2007. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: Two case studies. J Clin Pathol 60:1013-1016.
9. Gray SG, Eriksson T, Ekstrom C, Holm S, vonSchweinitz D, Koqner P, Sandstedt B, Pietsch T, Ekstrom TJ. 2000. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 82:1561-1567.
10. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. 1994. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54:2331-2333.
11. Hancock AL, Brown KW, Moorwood K, Moon H, Holmgren C, Mardikar SH, Dallosso AR, Klenova E, Loukinov D, Ohlsson R, Lobanenkov VV, Malik K. 2007. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis. Hum Mol Genet 16:343-354.
12. Hohensterin P, Hastie ND. 2006. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15:R196-R201.
13. Japanese Pathological Society. 1988. Committee on histological classification of childhood tumors: Tumors of the urinary system. Tokyo: Kanahara Shuppan.
14. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. 1993. WT-1 is required for early kidney development. Cell 74:679-691.
15. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, D'Agati V, Licht JD, Tycko B. 2004. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165:1943-1953.
16. Little MH, Dunn R, Byrne JA, Seawriqht A, Smith PJ, Pritchard-Jones K, Hevninqen V, Hastie ND. 1992. Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms' tumours. Oncogene 7:635-641.
17. Little M, Wells C. 1997. A clinical overview of WT1 gene mutations. Hum Mut 9:209-225.
18. Maiti S, Alam R, Amos CI, Huff V. 2000. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res 60:6288-6292.
19. Nakadate H, Tsuchiya T, Maseki N, Hatac Y, Tsunematsu Y, Horikoshi Y, Ishida Y, Kikuta A, Eguchi H, Endo M, Miyake M, Sakurai M, Kaneko Y. 1999. Correlation of chromosome abnormalities with presence or absence of WT1 deletions/mutations in Wilms tumor. Genes Chromosomes Cancer 25:26-32.
20. Nakadate H, Yokomori K, Watanabe N, Tsuchiya T, Namiki T, Kobayashi H, Suita S, Tsunematsu Y, Horikoshi Y, Hatae Y, Endo M, Komada Y, Eguchi H, Toyoda Y, Kikuta A, Kobayashi R, Kaneko Y. 2001. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan. Int J Cancer 94:396-400.
21. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079.
22. Nordenskjold A, Friedman E, Anvret M. 1994. WT1 mutations in patients with Denys-Drash syndrome: A novel mutation in exon 8 and paternal allele origin. Hum Genet 93:115-120.
23. Perlman EJ, Grosfeld JL, Togasi K, Boccon-Gibod L. 2004. Pathology and genetics of tumours of the urinary system and male genital organs. In: Eble JN, Sauter G, Epstein JI, Sesterhern IA, editors. World Health Organization Classification of Tumours. Lyon: IARC press.
24. Perotti D, De Vecchi G, Testi MA, Lualdi E, Modena P, Mondini P, Ravagnani F, Collini P, Di Renzo F, Spreafico F, Terenziani M, Sozzi G, Fossati-Bellani F, Radice P. 2004. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Hum Mutat 24:400-407.
25. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP. 2001. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93:1698-1703.
26. Rivera MN, Haber DA. 2005. Wilms' tumour: Connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 5:699-712.
27. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. 2007. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315:642-645.
28. Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, Huff V. 2004. Twenty-four new cases of WT1 germline mutations and review of the literature: Genotype/phenotype correlations for Wilms tumor development. Am J Med Genet 127:249-257.
29. Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. 2005. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 43:172-180.
30. Satoh Y, Nakagawachi T, Nakadate H, Kaneko Y, Masaki Z, Mukai T, Soejima H. 2003. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. J Biochem 133:303-308.
31. Satoh Y, Nakadate H, Nakagawachi T, Higashimoto K, Joh K, Masaki Z, Uozumi J, Kaneko Y, Mukai T, Soejima H. 2006. Genetic and epigenetic alterations in the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumor. Br J Cancer 95:541-547.
32. Scharnhorst V, van der Eb AJ, Jochemsen AG. 2001. WT1 proteins: Functions in growth and diffetentiation. Gene 273:141-161.
33. Schroeder WT, Chao LY, Dao DD, Strong LC, Pathak S, Riccardi V, Lewis WH, Saunders GF. 1987. Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet 40:413-420.
34. Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D, Schmidt D, Weirich A, Ludwig R, Royer-Pokora B. 1997. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci USA 94:3972-3977.
35. Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I, Harms D, Licht J, Roberts S, Royer-Pokora B. 2003. Two molecular subgroups of Wilms' tumors with or without WT1 mutations. Clin Cancer Res 9:2005-2014.
36. Sossey-Alaoui K, Vieira L, David D, Boavida MG, Cowell JK. 2003. Molecular characterization of a 7p15-p21 homozygous deletion in a Wilms tumor. Genes Chromosomes Cancer 36:1-6.
37. Sugawara W, Haruta M, Sasaki F, Watanabe N, Tsunematsu Y, Kikuta A, Kaneko Y. 2007. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 49:240-249.
38. Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA. 2001. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10:2619-2626.
39. Watanabe N, Haruta M, Soejima H, Fukushi D, Yokomori K, Nakadate Y, Okita H, Hata JI, Fukuzawa M, Kaneko Y. 2007. Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type. Genes Chromosomes Cancer 46:929-935.
40. Watanabe N, Nakadate H, Haruta M, Sugawara W, Sasaki F, Tsunematsu Y, Kikuta A, Fukuzawa M, Okita H, Hata J, Hidenobu H, Kaneko Y. 2006. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 45:592-601.
41. Yuan E, Li CM, Yamamoto DJ, Kandel J, Thaker H, Murty VV, Tycko B. 2005. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 3:493-502.
42. Zhan S, Shapiro DN, Helman LJ. 1994. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94:445-448.